We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-24.74%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
AUM
$255M
AUM Growth
-$90M
Cap. Flow
-$751K
Cap. Flow %
-0.29%
Top 10 Hldgs %
100%
Holding
9
New
Increased
3
Reduced
Closed
2

Top Buys

Rank Stock Value
1
YPF icon
YPF
YPF
+$16.9M
2
LNG icon
Cheniere Energy
LNG
+$376K
3
MTW icon
Manitowoc
MTW
+$171K

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$16M
2
ARDX icon
Ardelyx
ARDX
+$2.19M

Sector Composition

Rank Sector Weight
1 Energy 42%
2 Financials 28.05%
3 Industrials 23.4%
4 Real Estate 6.55%
5 Healthcare 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALLY icon
1
Ally Financial
ALLY
$14B
$71.4M 28.05%
3,504,000
MTW icon
2
Manitowoc
MTW
$468M
$54.8M 21.54%
4,035,360
+11,041
+0.3% +$171K
LNG icon
3
Cheniere Energy
LNG
$55B
$46.7M 18.35%
967,000
+6,100
+0.6% +$376K
YPF icon
4
YPF
YPF
$19.5B
$32.9M 12.92%
2,159,494
+756,000
+54% +$16.9M
AR icon
5
Antero Resources
AR
$10.4B
$27.3M 10.74%
1,291,733
IRS
6
IRSA Inversiones y Representaciones
IRS
$1.28B
$16.7M 6.55%
1,190,846
CRESY
7
Cresud
CRESY
$762M
$4.75M 1.87%
545,481
ARDX icon
8
Ardelyx
ARDX
$1.28B
-136,866
Closed -$2.19M
KERX
9
DELISTED
Keryx Biopharmaceuticals Inc
KERX
-1,605,800
Closed -$16M

Similar funds

Finepoint Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Finepoint Capital held 9 positions worth $255M, down 26% from $345M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Finepoint Capital's Q3 2015 filing shows 3 increased and 2 closed positions. The largest sale was Keryx Biopharmaceuticals Inc, an estimated $16M.

By sector, the portfolio is most concentrated in Energy at 42% of assets, down from 43% a quarter earlier, followed by Financials and Industrials.

  • Finepoint Capital added most to YPF in Q3 2015, an estimated $16.9M increase.
  • Finepoint Capital fully exited Keryx Biopharmaceuticals Inc in Q3 2015, selling an estimated $16M.
  • Finepoint Capital's ten largest holdings make up 100% of its $255M portfolio in Q3 2015.
  • Finepoint Capital opened 0 new positions and closed 2 in Q3 2015.
  • Finepoint Capital's portfolio value fell 26% quarter-over-quarter to $255M.

Based on Finepoint Capital's 13F filing for Q3 2015, filed 13 Nov 2015.